Company Description
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel.
It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma.
The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors.
In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome.
Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
| Country | United States |
| Founded | 2017 |
| Industry | Real Estate Services |
| Sector | Real Estate |
| Employees | 13 |
| CEO | William Conkling |
Contact Details
Address: 520 Broad Street Newark, New Jersey 07102 United States | |
| Phone | 212 658 1450 |
| Website | rafaelholdings.com |
Stock Details
| Ticker Symbol | RFL |
| Exchange | NYSE |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0001713863 |
| CUSIP Number | 75062E106 |
| ISIN Number | US75062E1064 |
| Employer ID | 82-2296593 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William Conkling | Chief Executive Officer and President |
| Howard S. Jonas | Founder and Executive Chairman |
| Barbara A. Ryan | Investor Relations Officer |
| Gus Kodersha | Chief Technical Operations Officer |
| Dr. Rick Ewing | Head of Drug Discovery |
| Joyce J. Mason Esq. | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 7, 2024 | 10-K | Annual Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 30, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Oct 9, 2024 | S-4 | Filing |
| Sep 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 22, 2024 | 425 | Filing |
| Aug 22, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |